Kooth (KOO) Competitors

GBX 136.85 -1.15 (-0.83%)

As of 03:48 AM Eastern

KOO vs. COG, INHC, RENX, FDBK, and IQAI

Should you buy Kooth stock or one of its competitors? MarketBeat compares Kooth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kooth include Cambridge Cognition (COG), Induction Healthcare Group (INHC), Renalytix (RENX), Feedback (FDBK), and IQ-AI (IQAI). These companies are all part of the "health information services" industry.

How does Kooth compare to Cambridge Cognition?

Kooth (LON:KOO) and Cambridge Cognition (LON:COG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Kooth has a beta of 1.238, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.832, suggesting that its share price is 17% less volatile than the broader market.

In the previous week, Kooth had 2 more articles in the media than Cambridge Cognition. MarketBeat recorded 2 mentions for Kooth and 0 mentions for Cambridge Cognition. Kooth's average media sentiment score of 0.51 beat Cambridge Cognition's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Overall Sentiment
Kooth	Positive
Cambridge Cognition	Neutral

Kooth presently has a consensus target price of GBX 330, suggesting a potential upside of 141.14%. Cambridge Cognition has a consensus target price of GBX 56, suggesting a potential upside of 51.35%. Given Kooth's higher possible upside, research analysts clearly believe Kooth is more favorable than Cambridge Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

21.7% of Kooth shares are held by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are held by institutional investors. 30.6% of Kooth shares are held by insiders. Comparatively, 3.4% of Cambridge Cognition shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kooth has a net margin of 4.12% compared to Cambridge Cognition's net margin of -17.82%. Kooth's return on equity of 8.84% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

Kooth has higher revenue and earnings than Cambridge Cognition. Cambridge Cognition is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.78	£4.00M	£7.00	19.55
Cambridge Cognition	£9.40M	1.83	-£1.58M	-£3.90	N/A

Summary

Kooth beats Cambridge Cognition on 14 of the 15 factors compared between the two stocks.

How does Kooth compare to Induction Healthcare Group?

Kooth (LON:KOO) and Induction Healthcare Group (LON:INHC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Kooth has a beta of 1.238, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Induction Healthcare Group has a beta of -0.41, suggesting that its share price is 141% less volatile than the broader market.

In the previous week, Kooth had 2 more articles in the media than Induction Healthcare Group. MarketBeat recorded 2 mentions for Kooth and 0 mentions for Induction Healthcare Group. Kooth's average media sentiment score of 0.51 beat Induction Healthcare Group's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Overall Sentiment
Kooth	Positive
Induction Healthcare Group	Neutral

Kooth presently has a consensus target price of GBX 330, suggesting a potential upside of 141.14%. Given Kooth's stronger consensus rating and higher possible upside, research analysts clearly believe Kooth is more favorable than Induction Healthcare Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Induction Healthcare Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Kooth has higher revenue and earnings than Induction Healthcare Group. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.78	£4.00M	£7.00	19.55
Induction Healthcare Group	£12.57M	0.72	-£5.12M	-£5.54	N/A

Kooth has a net margin of 4.12% compared to Induction Healthcare Group's net margin of -23.86%. Kooth's return on equity of 8.84% beat Induction Healthcare Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
Induction Healthcare Group	-23.86%	-14.58%	-7.32%

21.7% of Kooth shares are held by institutional investors. Comparatively, 46.3% of Induction Healthcare Group shares are held by institutional investors. 30.6% of Kooth shares are held by insiders. Comparatively, 54.6% of Induction Healthcare Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Kooth beats Induction Healthcare Group on 14 of the 16 factors compared between the two stocks.

How does Kooth compare to Renalytix?

Kooth (LON:KOO) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Kooth had 1 more articles in the media than Renalytix. MarketBeat recorded 2 mentions for Kooth and 1 mentions for Renalytix. Kooth's average media sentiment score of 0.51 beat Renalytix's score of -1.02 indicating that Kooth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kooth	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Renalytix	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Kooth has a beta of 1.238, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Renalytix has a beta of 1.974, meaning that its stock price is 97% more volatile than the broader market.

Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.78	£4.00M	£7.00	19.55
Renalytix	£3.30M	2.30	-£109.93M	-£4.00	N/A

Kooth presently has a consensus target price of GBX 330, suggesting a potential upside of 141.14%. Given Kooth's stronger consensus rating and higher probable upside, analysts plainly believe Kooth is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Kooth has a net margin of 4.12% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat Kooth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
Renalytix	-680.00%	274.67%	-93.54%

21.7% of Kooth shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 30.6% of Kooth shares are owned by insiders. Comparatively, 5.1% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Kooth beats Renalytix on 13 of the 16 factors compared between the two stocks.

How does Kooth compare to Feedback?

Feedback (LON:FDBK) and Kooth (LON:KOO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Feedback has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Kooth has a beta of 1.238, suggesting that its stock price is 24% more volatile than the broader market.

Kooth has a net margin of 4.12% compared to Feedback's net margin of -845.25%. Kooth's return on equity of 8.84% beat Feedback's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Feedback	-845.25%	-135.17%	-22.99%
Kooth	4.12%	8.84%	10.12%

35.7% of Feedback shares are held by institutional investors. Comparatively, 21.7% of Kooth shares are held by institutional investors. 8.0% of Feedback shares are held by company insiders. Comparatively, 30.6% of Kooth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Kooth has a consensus target price of GBX 330, suggesting a potential upside of 141.14%. Given Kooth's stronger consensus rating and higher possible upside, analysts plainly believe Kooth is more favorable than Feedback.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Feedback	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kooth has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Feedback	£849.62K	4.64	-£10.84M	-£15.74	N/A
Kooth	£63.29M	0.78	£4.00M	£7.00	19.55

In the previous week, Kooth had 2 more articles in the media than Feedback. MarketBeat recorded 2 mentions for Kooth and 0 mentions for Feedback. Kooth's average media sentiment score of 0.51 beat Feedback's score of 0.00 indicating that Kooth is being referred to more favorably in the news media.

Company	Overall Sentiment
Feedback	Neutral
Kooth	Positive

Summary

Kooth beats Feedback on 14 of the 16 factors compared between the two stocks.

How does Kooth compare to IQ-AI?

Kooth (LON:KOO) and IQ-AI (LON:IQAI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Kooth has a beta of 1.238, suggesting that its share price is 24% more volatile than the broader market. Comparatively, IQ-AI has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

Kooth has higher revenue and earnings than IQ-AI.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.78	£4.00M	£7.00	19.55
IQ-AI	£538.19K	3.30	N/A	N/A	N/A

In the previous week, Kooth had 2 more articles in the media than IQ-AI. MarketBeat recorded 2 mentions for Kooth and 0 mentions for IQ-AI. Kooth's average media sentiment score of 0.51 beat IQ-AI's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Overall Sentiment
Kooth	Positive
IQ-AI	Neutral

Kooth presently has a consensus target price of GBX 330, indicating a potential upside of 141.14%. Given Kooth's stronger consensus rating and higher possible upside, equities analysts plainly believe Kooth is more favorable than IQ-AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
IQ-AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

21.7% of Kooth shares are owned by institutional investors. 30.6% of Kooth shares are owned by insiders. Comparatively, 66.0% of IQ-AI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kooth has a net margin of 4.12% compared to IQ-AI's net margin of -77.52%. Kooth's return on equity of 8.84% beat IQ-AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
IQ-AI	-77.52%	-140.75%	-22.03%

Summary

Kooth beats IQ-AI on 11 of the 14 factors compared between the two stocks.

Get Kooth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KOO vs. The Competition

Export

Metric	Kooth	Health Information Services Industry	Medical Sector	LON Exchange
Market Cap	£49.64M	£306.97M	£6.30B	£2.78B
Dividend Yield	N/A	5.59%	2.79%	6.09%
P/E Ratio	19.55	181.02	21.00	365.88
Price / Sales	0.78	125.42	554.55	88,361.46
Price / Cash	5.42	47.14	42.94	27.89
Price / Book	2.12	5.36	9.75	7.64
Net Income	£4.00M	-£22.78M	£3.55B	£5.89B
7 Day Performance	2.13%	0.43%	-0.53%	0.47%
1 Month Performance	0.26%	-2.11%	1.20%	2.49%
1 Year Performance	0.27%	-9.96%	41.22%	87.07%

Kooth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KOO Kooth	2.9212 of 5 stars	GBX 136.85 -0.8%	GBX 330 +141.1%	-0.2%	£49.64M	£63.29M	19.55	478	Gap Down
COG Cambridge Cognition	1.1687 of 5 stars	GBX 36.10 +1.7%	GBX 56 +55.1%	-10.3%	£16.81M	£9.05M	N/A	80	Gap Up
INHC Induction Healthcare Group	N/A	GBX 9.75 flat	N/A	+1.6%	£9.00M	£12.57M	N/A	74
RENX Renalytix	N/A	GBX 2 +11.1%	N/A	-79.6%	£8.74M	£3.30M	N/A	102	Gap Down
FDBK Feedback	N/A	GBX 9.50 -2.6%	N/A	-34.5%	£4.16M	£849.62K	N/A	24

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:KOO) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kooth (KOO) Competitors

KOO vs. COG, INHC, RENX, FDBK, and IQAI

How does Kooth compare to Cambridge Cognition?

Summary

How does Kooth compare to Induction Healthcare Group?

Summary

How does Kooth compare to Renalytix?

Summary

How does Kooth compare to Feedback?

Summary

How does Kooth compare to IQ-AI?

Summary

Media Sentiment Over Time

KOO vs. The Competition

Kooth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kooth (KOO) Competitors

KOO vs. COG, INHC, RENX, FDBK, and IQAI

How does Kooth compare to Cambridge Cognition?

Which has more volatility & risk, KOO or COG?

Does the media favor KOO or COG?

Do analysts prefer KOO or COG?

Do insiders & institutionals hold more shares of KOO or COG?

Is KOO or COG more profitable?

Which has stronger earnings and valuation, KOO or COG?

Summary

How does Kooth compare to Induction Healthcare Group?

Which has more volatility & risk, KOO or INHC?

Does the media favor KOO or INHC?

Do analysts prefer KOO or INHC?

Which has stronger earnings and valuation, KOO or INHC?

Is KOO or INHC more profitable?

Do insiders & institutionals hold more shares of KOO or INHC?

Summary

How does Kooth compare to Renalytix?

Does the media refer more to KOO or RENX?

Which has more risk & volatility, KOO or RENX?

Which has preferable valuation & earnings, KOO or RENX?

Do analysts prefer KOO or RENX?

Is KOO or RENX more profitable?

Do institutionals & insiders hold more shares of KOO or RENX?

Summary

How does Kooth compare to Feedback?

Which has more volatility and risk, FDBK or KOO?

Is FDBK or KOO more profitable?

Do institutionals and insiders hold more shares of FDBK or KOO?

Do analysts recommend FDBK or KOO?

Which has stronger earnings & valuation, FDBK or KOO?

Does the media prefer FDBK or KOO?

Summary

How does Kooth compare to IQ-AI?

Which has more volatility and risk, KOO or IQAI?

Which has better valuation and earnings, KOO or IQAI?

Does the media refer more to KOO or IQAI?

Do analysts rate KOO or IQAI?

Do insiders & institutionals believe in KOO or IQAI?

Is KOO or IQAI more profitable?

Summary

Media Sentiment Over Time

KOO vs. The Competition

Kooth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools